TBPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theravance Biopharma Inc (TBPH) is not a good buy for a beginner, long-term investor at this time. The stock faces significant negative catalysts, weak financial performance, and lacks clear growth drivers. Additionally, the technical indicators and options data do not suggest a strong entry point.
The MACD is positive at 0.347 but contracting, RSI is at 76.59 in the neutral zone, and moving averages are converging, indicating no strong trend. The stock is trading near resistance (R1: 16.731), with limited upside potential in the short term.
The company has secured exclusivity for its single-asset story through April 2039, removing some overhang. Yupelri continues to grow and generate milestones, and Trelegy payments remain significant.
The failure of the Phase 3 CYPRESS study has led to significant cost cuts and a strategic reset. The company faces legal investigations for potential securities law violations, and there is no clear path forward for its ampreloxetine program. Analysts have lowered price targets, and the stock is expected to decline in the short to medium term.
In 2025/Q4, revenue increased by 144.70% YoY to $45.89M. However, net income dropped by -493.02% YoY to -$61.02M, EPS fell by -764.52% YoY to -2.06, and gross margin dropped to 0%. The company is undergoing significant cost reductions.
Analyst sentiment is mixed to negative. Recent upgrades have been cautious, with price targets raised to $15-$17 but maintaining Neutral or Hold ratings. Downgrades cite the failure of the CYPRESS study and limited visibility into future growth drivers.
